Takeda's seizure drug fails to meet main goal in late-stage studies (updated)

Ovid Therapeutics

17/06/2024 12:07

(Adds details throughout)
       June 17 (Reuters) - Japan's Takeda  4502.T  said on
Monday its experimental drug to treat epileptic disorders failed
to meet the main goal in two late-stage studies.
    The drug, soticlestat, was being tested in adult and
pediatric patients with Dravet syndrome and Lennox-Gastaut
syndrome.
    These are severe forms of epilepsy characterized by
frequent, prolonged seizures, that typically becomes apparent
during infancy or early childhood.
    Takeda plans to discuss with regulatory authorities to
determine next steps. 
        
     

 (Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh
Kuber)
 ((Mariam.ESunny@thomsonreuters.com;))